2 results match your criteria: "a Dana Center for Preventive Ophthalmology[Affiliation]"
Ocular Chlamydia trachomatis infection: elimination with mass drug administration.
Expert Rev Anti Infect Ther
March 2019
a Dana Center for Preventive Ophthalmology, Johns Hopkins Medical Institutions , Baltimore , MD , USA.
Ocular Chlamydia trachomatis infection, the causative agent for trachoma, is responsible for 1.9 million cases of visual loss worldwide. Mass Drug Administration (MDA) with azithromycin to entire trachoma-endemic districts is part of the World Health Organization's public health strategy for trachoma elimination.
View Article and Find Full Text PDFSurveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
Ophthalmic Epidemiol
December 2016
a Dana Center for Preventive Ophthalmology, Wilmer Eye Institute , Johns Hopkins University, Baltimore , MD , USA.
Purpose: Immigrants and travelers may be sources of re-emergent infection in trachoma-endemic communities close to trachoma elimination. The primary objective of the A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) trial was to determine whether a newcomer and traveler surveillance and treatment program in addition to annual mass drug administration (MDA) would reduce Chlamydia trachomatis infection when compared to MDA alone.
Methods: ASANTE was a randomized controlled trial in 52 communities in Kongwa, Tanzania.